Cardiometabolic Disorders News

The American Diabetes Association and Kidney Disease: Improving Global Outcomes have released a consensus report addressing diabetes management in chronic kidney disease.

NATIONAL HARBOR, Md. — In a DELIVER subgroup analysis, dapagliflozin conferred similar benefit in patients with HF with improved ejection fraction prior to trial enrollment compared with those with consistently high EF.

Women who combine time-restricted eating with high-intensity interval training have greater reductions in visceral fat area than those who perform only one of the interventions, according to a study published in Cell Metabolism.

Prescription rates of SGLT2 inhibitors and GLP-1 receptor agonists among adults with type 2 diabetes in the Veterans Health Administration varied by race, with white patients most likely to receive these medications.

Healio and the Cardiometabolic Health Congress are proud to partner for the 17th Annual Cardiometabolic Health Congress: The Present and Future of Cardiometabolic Health in Boston this fall.

In adults with HF, empagliflozin was associated with a reduction in new macroalbuminuria in patients with macroalbuminuria at baseline compared with placebo.

As a valued ally in delivering the latest news, resources and education to busy medical providers, Healio has committed its support to the 17th Annual Cardiometabolic Health Congress: The Present and Future of Cardiometabolic Health.

Adults with obesity — but not those with normal weight — who try to lose weight lower their risk for developing type 2 diabetes regardless of weight-loss strategy, according to study findings published in PLOS Medicine.

Once-weekly semaglutide 2.4 mg reduces the 10-year risk for developing type 2 diabetes by more than 60% for people with overweight or obesity, according to a speaker at the European Association for the Study of Diabetes annual meeting.

Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.